Company intelligence / Profile preview

Dominari Holdings

New York, New York, United Statesdominariholdings.com ↗

Ownership: Public · DOMH
Employees: ~7
Development stage: Other

Overview

Dominari Holdings develops small-molecule therapeutics targeting oncology indications such as pancreatic cancer and leukemias as well as a broad-spectrum antiviral program. Lead assets include DHA-dFdC for pancreatic cancer and KPC34 for AML/ALL. The company also has an antiviral platform with activity against multiple high-concern viruses. No late-stage clinical results or approvals have been reported publicly as of June 2025.

Therapeutic areas: Infectious DiseasesHematologyOncology
Modalities: Small moleculeChemotherapyAntiviral therapy
Industry: Biotech

Drug pipeline

1 asset

DHA-dFdC

Preclinical

Partnerships

University of Texas at AustinUniversity of Maryland BaltimoreWake Forest University Health SciencesSilo Pharma Inc.

Beyond the preview

Go deeper on Dominari Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dominari Holdings.

Explore the full profile